This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 8, 2012 4:30 PM ET
Catherine O’Connor – IR
Roger Hawley – CEO
Ann Rhoads – EVP, CFO, Treasurer and Secretary
Stephen Farr – President and COO
Michael Tong – Wells Fargo Securities
Michael Schmidt – Leerink Swann
Josh (ph) – Stifel Nicolaus
Chris Holterhoff – Oppenheimer
Good day ladies and gentlemen, and welcome to the second quarter 2012 Zogenix, Inc. conference call. My name is Erica (ph) and I will be your coordinator for today. At this time all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. (Operator Instructions). I would now like to turn the presentation over to your host for today’s call, Ms. Catherine O’Connor. Please proceed.
Thank you, Operator, and thank you all for joining us this afternoon. With me on today’s call are Roger Hawley, our Chief Executive Officer; Dr. Stephen Farr, our President and Chief Operating Officer; and Ann Rhoads, our Executive Vice President and Chief Financial Officer.
Earlier today Zogenix issued a news release announcing the company’s financial results for the second quarter 2012. We encourage everyone to read today’s news release as well as Zogenix’s quarterly report on Form 10-Q which will be available on our website at www.Zogenix.com.
Roger will open the call with an update on SUMAVEL DosePro. Ann will then review our financial results for the second quarter 2012 and Steve will follow with an update on our development programs including the NDA filings for Zohydro. At the end of the prepared remarks we will open up the call for a question and answer session.